Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIIOngoingJan 21, 2026Fluocinolone Acetonide Solution Topical Solution USPFailed Impurities/Degradation Specifications: Out of specification result was obtained for the known impurity D.Sun Pharmaceutical Industries Inc · D-0256-2026Class IIOngoingJan 14, 2026Rosuvastatin TabletsOut of specification for dissolution.AvKARE · D-0292-2026Class IOngoingJan 14, 2026ClearLife Allergy Nasal SprayMicrobial Contamination of Non-Sterile Products: The products have been found to contain yeast/mold and microbial contamination identified as Achromobacter.Medinatura New Mexico, inc. · D-0289-2026Class IOngoingJan 14, 2026ReBoost Nasal SprayMicrobial Contamination of Non-Sterile Products: The products have been found to contain yeast/mold and microbial contamination identified as Achromobacter.Medinatura New Mexico, inc. · D-0288-2026Class IIOngoingJan 14, 2026Oxycodone and Acetaminophen CII Tablets USPFailed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets.SpecGx, LLC · D-0255-2026Class IIOngoingJan 14, 2026Oxycodone and Acetaminophen CII Tablets USPFailed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets.SpecGx, LLC · D-0254-2026Class IIOngoingJan 14, 2026ORL Kids Natural ToothpastecGMP DeviationsSignature Formulations, LLC · D-0253-2026Class IIOngoingJan 14, 2026ORL Kids MouthwashcGMP DeviationsSignature Formulations, LLC · D-0252-2026Class IIOngoingJan 14, 2026Tri-Moxi+¿Presence of particulate matter - Glass like particles.Imprimis NJOF, LLC · D-0251-2026Class IIOngoingJan 14, 2026Dexamethasone Moxifloxacin KetorolacPresence of particulate matter - Glass like particles.Imprimis NJOF, LLC · D-0250-2026Class IIOngoingJan 14, 2026Dexamethasone MoxifloxacinPresence of particulate matter - Glass like particles.Imprimis NJOF, LLC · D-0249-2026Class IIIOngoingJan 14, 2026Fesoterodine FumarateFailed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.Alembic Pharmaceuticals Limited · D-0248-2026Class IIIOngoingJan 7, 2026traZODONE Hydrochloride TabletsFailed Tablet/Capsule Specifications: Product complaint received that some tablets had a dent on the plain side of the tablet surface.Zydus Pharmaceuticals (USA) Inc · D-0247-2026Class IIOngoingJan 7, 2026Ondansetron Orally Disintegrating TabletsDefective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out...Glenmark Pharmaceuticals Inc., USA · D-0246-2026Class IIOngoingJan 7, 2026Wegovy (semaglutide) InjectionPresence of Particulate Matter: Hair was found in a prefilled syringeNovo Nordisk Inc. · D-0245-2026Class IIOngoingJan 7, 2026Wegovy (semaglutide) InjectionPresence of Particulate Matter: Hair was found in a prefilled syringeNovo Nordisk Inc. · D-0244-2026Class IIOngoingJan 7, 2026BD ChloraPrep" Triple SwabsticksLack of Assurance of SterlityCareFusion 213, LLC · D-0243-2026Class IIOngoingDec 31, 2025Noxafil PowdermixPresence of particulate matter: potential presence of metal particulates in the product.Merck Sharp & Dohme LLC · D-0242-2026Class IIOngoingDec 31, 2025Merck EmendPresence of particulate matter: potential presence of metal particulates in the product.Merck Sharp & Dohme LLC · D-0241-2026Class IIOngoingDec 24, 2025Ciclopirox ShampooFailed Impurity/Degradation specifications: OOS results obtained at the 18-month timepointSun Pharma /Taro · D-0240-2026Class IIOngoingDec 24, 2025Ondansetron ODT TabletsDefective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out...Preferred Pharmaceuticals, Inc. · D-0239-2026Class IIIOngoingDec 24, 2025Cisatracurium Besylate Injection USPSubpotent product:out of specification assay results observed during long term stability testing.Somerset Therapeutics LLC · D-0238-2026Class IIIOngoingDec 24, 2025Cisatracurium Besylate Injection USPSubpotent product:out of specification assay results observed during long term stability testing.Somerset Therapeutics LLC · D-0237-2026Class IIIOngoingDec 24, 2025Cisatracurium Besylate Injection USPSubpotent product:out of specification assay results observed during long term stability testing.Somerset Therapeutics LLC · D-0236-2026Class IIOngoingDec 24, 2025Baclofen Tablets USPPresence of Foreign Tablets/CapsulesGolden State Medical Supply Inc. · D-0235-2026Class IIOngoingDec 24, 2025OraVerseDefective container: cracked/broken cartridgesNovocol Pharmaceutical of Canada, Inc. · D-0234-2026Class IIOngoingDec 24, 2025Cook-WalteDefective container: cracked/broken cartridgesNovocol Pharmaceutical of Canada, Inc. · D-0233-2026Class IIOngoingDec 24, 2025Benco dental Graham CHEMICAL CODefective container: cracked/broken cartridgesNovocol Pharmaceutical of Canada, Inc. · D-0232-2026Class IIOngoingDec 24, 2025darby dental supplyDefective container: cracked/broken cartridgesNovocol Pharmaceutical of Canada, Inc. · D-0231-2026Class IIOngoingDec 24, 20253% Polocaine DENTALDefective container: cracked/broken cartridgesNovocol Pharmaceutical of Canada, Inc. · D-0230-2026Class IIOngoingDec 24, 2025Lidocaine HCI 2% and Epinephrine 1:100Defective container: cracked/broken cartridgesNovocol Pharmaceutical of Canada, Inc. · D-0229-2026Class IIOngoingDec 24, 20252% Xylocaine DENTAL with Epinephrine 1:100Defective container: cracked/broken cartridgesNovocol Pharmaceutical of Canada, Inc. · D-0228-2026Class IIOngoingDec 17, 2025Sertraline Hydrochloride Tablets USPDefective container - seal not adhering to bottlesLupin Pharmaceuticals Inc. · D-0227-2026Class IIOngoingDec 17, 2025Cinacalcet Hydrochloride TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Cipla USA, Inc. · D-0226-2026Class IIOngoingDec 17, 2025Cinacalcet Hydrochloride TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Cipla USA, Inc. · D-0225-2026Class IIOngoingDec 17, 2025Cinacalcet Hydrochloride TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Cipla USA, Inc. · D-0224-2026Class IIIOngoingDec 17, 2025Morphine Sulfate Oral Solution 100 mg / 5 mLCorrect Labeled Product Mispack-Size stated on carton label did not match the size of the bottle in the carton.Winder Laboratories, LLC · D-0223-2026Class IIIOngoingDec 17, 2025Nebivolol TabletsCross Contamination with Other ProductsGlenmark Pharmaceuticals Inc., USA · D-0222-2026Class IIOngoingDec 17, 2025Tropicamide 1%/Cyclopentolate 1%/Phenylephrine 2.5%/Ketorolac 0.5% Topical Ophthalmic SolutionIncorrect Product FormulationFagron Compounding Services · D-0221-2026Class IIOngoingDec 17, 2025Ganirelix Acetate InjectionFailed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.Lupin Pharmaceuticals Inc. · D-0220-2026